317 related articles for article (PubMed ID: 25727644)
41. Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma.
Terra SBSP; Roden AC; Aubry MC; Yi ESJ; Boland JM
Arch Pathol Lab Med; 2021 Feb; 145(2):208-213. PubMed ID: 33501493
[TBL] [Abstract][Full Text] [Related]
42. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours.
Provenzano E; Byrne DJ; Russell PA; Wright GM; Generali D; Fox SB
Histopathology; 2016 Feb; 68(3):367-77. PubMed ID: 26118394
[TBL] [Abstract][Full Text] [Related]
43. Metastatic metaplastic breast carcinoma mimicking pulmonary squamous cell carcinoma on fine-needle aspiration.
Nguyen DN; Kawamoto S; Cimino-Mathews A; Illei PB; Rosenthal DL; VandenBussche CJ
Diagn Cytopathol; 2015 Oct; 43(10):844-9. PubMed ID: 26238413
[TBL] [Abstract][Full Text] [Related]
44. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
[TBL] [Abstract][Full Text] [Related]
45. [Surfactant protein and thyroid transcription factor 1 in pleuro-pulmonary neoplasia. Immunohistochemical study].
Dessy E; Falleni M; Del Curto B; Braidotti P; Pietra GG
Pathologica; 2000 Dec; 92(6):496-502. PubMed ID: 11234300
[TBL] [Abstract][Full Text] [Related]
46. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
[TBL] [Abstract][Full Text] [Related]
47. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
48. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
[TBL] [Abstract][Full Text] [Related]
49. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
51. GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15.
Zhao M; Zhou L; Sun L; Song Y; Guo Y; Zhang X; Zhao F; Wang P; Yue J; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Diagn Pathol; 2017 Jul; 12(1):51. PubMed ID: 28693610
[TBL] [Abstract][Full Text] [Related]
52. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
Galloway ML; Murray D; Moffat DF
Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
[No Abstract] [Full Text] [Related]
53. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
Bakir K; Koçer NE; Deniz H; Güldür ME
Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
[TBL] [Abstract][Full Text] [Related]
54. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
55. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
56. Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.
Törrönen K; Soini Y; Pääkkö P; Parkkinen J; Sironen R; Rilla K
Histol Histopathol; 2016 Oct; 31(10):1113-22. PubMed ID: 26912058
[TBL] [Abstract][Full Text] [Related]
57. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
58. Utility of GATA3, mammaglobin, GCDFP-15, and ER in the detection of intrathoracic metastatic breast carcinoma.
Dyhdalo KS; Booth CN; Brainard JA; Croyle MC; Kolosiwsky AM; Goyal A; Gildea TR; Almeida FA; Nassar A; Reynolds JP
J Am Soc Cytopathol; 2015; 4(4):218-224. PubMed ID: 31051757
[TBL] [Abstract][Full Text] [Related]
59. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
